MSI-H
-
First-line immunotherapy reduced progression hazard 39% in MSI-H metastatic colorectal cancer
A meta-analysis of two randomised phase III trials found longer progression-free and overall survival with first-line checkpoint-inhibitor therapy than chemotherapy in MSI-H/dMMR metastatic colorectal cancer. The evidence is…